Friday, 24 November 2017

Lupin receives FDA approval for generic Axiron topical solution

27 October 2017 | News

Lupin’s Testosterone Topical Solution, 30 mg per actuation is therapeutically equivalent to Eli Lilly and Company’s Axiron Topical Solution, 30 mg per actuation

Source: Pixabay

Source: Pixabay

Pharma Major Lupin has received final approval for its Testosterone Topical Solution, 30 mg per actuation from the United States Food and Drug Administration (FDA) to market a generic version of Eli Lilly and Company’s Axiron® Topical Solution, 30 mg per actuation.

Lupin’s Testosterone Topical Solution, 30 mg per actuation is therapeutically equivalent to Eli Lilly and Company’s Axiron® Topical Solution, 30 mg per actuation. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

Testosterone Topical Solution, 30 mg per actuation, had annual sales of approximately USD 244.2 million in the US. (IMS MAT June 2017).

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Are Indian drug firms still cautious of executing big mergers & acquistions?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls